Inhibition of PARP-1 leads to tyrosine phosphorylation of the vascular endothelial growth factor receptor-2 (VEGFR2), activation of AKT/PKB and disruption of NF-κB-mediated inflammation adding new aspects to the therapeutic use of these compounds in chronic inflammatory conditions like vascular disease or Diabetes mellitus [143, 169]. The gene discussed is AKT1; the disease is diabetes mellitus.